Efficacy and safety of Treamid in the rehabilitation of patients after COVID-19 pneumonia: a phase 2, randomized, double-blind, placebo-controlled trial.
Evgeny BazdyrevMaria PanovaMaria BrachsElena A SmolyarchukDaria TsygankovaLiudmila GofmanYana AbdyushevaFedor NovikovPublished in: Journal of translational medicine (2022)
4 weeks oral administration of 50 mg Treamid was associated with clinically significant improvement in the post-COVID patients, evident by an increase in FVC and/or DLCO as well as decreasing dyspnea. Treamid was well tolerated and can be safely administered to patients discharged after COVID. Treamid was more effective in women visible by superior improvement of COVID sequalae after 4 weeks treatment. Considering that female gender is a risk factor associated with the development of post-COVID symptoms, Treamid might offer a pharmacological treatment for long-term sequalae after COVID and supports further investigation in future clinical trials in post-COVID patients.
Keyphrases
- sars cov
- coronavirus disease
- double blind
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- placebo controlled
- respiratory syndrome coronavirus
- mental health
- prognostic factors
- phase iii
- palliative care
- phase ii
- metabolic syndrome
- adipose tissue
- study protocol
- pregnant women
- sleep quality
- skeletal muscle
- acute respiratory distress syndrome